0R15 8884.0068 1.4156% 0R1E 9171.0 0.4381% 0M69 None None% 0R2V 254.3746 5.7691% 0QYR 1619.0 1.9521% 0QYP 436.689 -0.8652% 0RUK None None% 0RYA 1604.02 0.4396% 0RIH 190.8 0.0% 0RIH 198.5 4.0356% 0R1O 225.0 9877.8271% 0R1O None None% 0QFP None None% 0M2Z 255.4879 -0.0829% 0VSO 33.09 -7.0636% 0R1I None None% 0QZI 599.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 225.74 -0.2871%

Gedeon Richter PLC

GB 0QFP

NoneGBP
-(-%)

Last update at 2024-12-23T18:00:02.989389Z

Day Range

--
LowHigh

52 Week Range

5036.109407.79
LowHigh

Fundamentals

  • Previous Close 5040.00
  • Market Cap1487271.00M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield4.89%
  • EBITDA214860.01M
  • Revenue TTM825947.98M
  • Revenue Per Share TTM4450.64
  • Gross Profit TTM 460464.00M
  • Diluted EPS TTM-

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax - - 115164.00M 50848.00M 43953.00M
Minority interest - - - - -
Net income - - 104683.00M 47135.00M 35348.00M
Selling general administrative - - 133766.00M 145281.00M 139654.00M
Selling and marketing expenses - - - - -
Gross profit - - 318770.00M 277779.00M 253836.00M
Reconciled depreciation - - - - -
Ebit 195318.00M 135351.00M 123700.00M 72493.00M 65690.00M
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income - - 111889.00M 39896.00M 45040.00M
Other operating expenses 7687.00M 9656.00M 7327.00M 11145.00M 7947.00M
Interest expense - 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - 9112.00M 2418.00M 7760.00M
Interest income - - 3287.00M 11086.00M 1932.00M
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 8408.00M 5395.00M 9112.00M 2418.00M 7760.00M
Total revenue - - 566776.00M 507794.00M 445484.00M
Total operating expenses - - - - -
Cost of revenue - - 248006.00M 230015.00M 191648.00M
Total other income expense net - - - - -
Discontinued operations - - - - -
Net income from continuing ops - - - - -
Net income applicable to common shares 155581.00M 139626.00M 104683.00M 47135.00M 35348.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - - 948589.00M 858651.00M 797883.00M
Intangible assets - - 141303.00M 127635.00M 151648.00M
Earning assets - - - - -
Other current assets 110288.00M 9910.00M 12470.00M 3979.00M 2308.00M
Total liab - - 141632.00M 140670.00M 117698.00M
Total stockholder equity - - 806957.00M 717981.00M 680185.00M
Deferred long term liab - - - - -
Other current liab 126123.00M 12770.00M 13093.00M 22877.00M 13170.00M
Common stock 18638.00M 18638.00M 18638.00M 18638.00M 18638.00M
Capital stock - - - - -
Retained earnings 966375.00M 849735.00M 751408.00M 653691.00M 626052.00M
Other liab 48125.00M 22545.00M 15153.00M 13920.00M 19985.00M
Good will - - 31398.00M 29503.00M 35386.00M
Other assets 50756.00M 15179.00M 9796.00M 11957.00M 16691.00M
Cash - - 141977.00M 122401.00M 112827.00M
Cash and equivalents - - - - -
Total current liabilities 179507.00M 123213.00M 107938.00M 109562.00M 92151.00M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - 10754.00M 10296.00M 2.00M
Other stockholder equity 51802.00M 34161.00M 25488.00M 34308.00M 22467.00M
Property plant equipment 315949.00M 278394.00M 254121.00M 244754.00M 214880.00M
Total current assets 575770.00M 412622.00M 449518.00M 409580.00M 358071.00M
Long term investments - - - - -
Net tangible assets 818091.00M 658966.00M 634256.00M 560843.00M 493151.00M
Short term investments - - 7142.00M 1545.00M 4728.00M
Net receivables 186176.00M 205426.00M 173126.00M 173157.00M 145327.00M
Long term debt - - - - 2.00M
Inventory 153335.00M 131349.00M 110059.00M 98995.00M 92687.00M
Accounts payable 46092.00M 79638.00M 65838.00M 61770.00M 54549.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - -3791.00000M -3870.00000M -2186.00000M
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total - - - - -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -44200.00000M -112208.00000M -36647.00000M -4474.00000M 15108.00M
Change to liabilities 48243.00M 17173.00M -4545.00000M 13452.00M 13300.00M
Total cashflows from investing activities -118827.00000M -249172.00000M -98891.00000M -59703.00000M -44374.00000M
Net borrowings -3437.00000M 68218.00M -3143.00000M -3793.00000M -3793.00000M
Total cash from financing activities -46909.00000M 25259.00M -18293.00000M -26182.00000M -16326.00000M
Change to operating activities - - - - -
Net income 155581.00M 139626.00M 104683.00M 47135.00M 35348.00M
Change in cash 20823.00M -82406.00000M 13689.00M 15552.00M 36980.00M
Begin period cash flow - - - - -
End period cash flow - - - - -
Total cash from operating activities 184927.00M 139904.00M 133520.00M 98214.00M 100343.00M
Issuance of capital stock - - - - -
Depreciation 48569.00M 44922.00M 39846.00M 39320.00M 34822.00M
Other cashflows from investing activities 13461.00M 3652.00M 3114.00M 915.00M 1364.00M
Dividends paid 41934.00M 41934.00M 11741.00M 18637.00M 12673.00M
Change to inventory -38994.00000M -20983.00000M -13900.00000M -6308.00000M -8772.00000M
Change to account receivables -51307.00000M -36470.00000M -3341.00000M -33063.00000M -4617.00000M
Sale purchase of stock - - -1650.00000M -3539.00000M -3653.00000M
Other cashflows from financing activities -212.00000M -206.00000M -1759.00000M -213.00000M -213.00000M
Change to netincome 22835.00M -4364.00000M 10777.00M 37678.00M 30177.00M
Capital expenditures 59231.00M 46127.00M 36903.00M 39507.00M 41954.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - - -29323.00000M -33280.00000M -6269.00000M
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow - - - - -

Peer Comparison

Sector: Industry:

Company Change (GBP) Price (GBP) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
0QFP
Gedeon Richter PLC
- -% - - - - -
0RIH
Alphabet Inc Class A
- -% 190.80 - - - -
0M2Z
Equinor ASA
-0.2121 0.08% 255.49 - - - -
0VSO
BYD Co. Ltd.
-2.515 7.06% 33.09 - - - -
0QZI
Facebook Inc. Cl A
- -% 599.00 - - - -

Reports Covered

Stock Research & News

Profile

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. researches, develops, manufactures, markets, and sells pharmaceutical products worldwide. The company operates through two segments, Pharmaceuticals, and Wholesale and Retail. It develops and manufactures products in various therapeutic areas, including women's healthcare, cardiovascular, and central nervous system. The company offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and aesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, an emergency contraceptive pill; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound care; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergy; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; Oralsept, a sore throat and local anesthetic. Further, it provides financial and accounting, social and welfare, portfolio and project management, catering, carriage transportation, engineering, quality control, trading, asset management, and biotechnological services. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. was founded in 1901 and is headquartered in Budapest, Hungary.

Gedeon Richter PLC

GyOemroi Ut 19-21., Budapest, Hungary, 1103

Key Executives

Name Title Year Born
Dr. Gabor Mihaly Gulacsi Chief Financial Officer 1958
Mr. Gábor Orbán CEO, Member of Exec. Board & Director 1979
Dr. István Greiner Research Director & Member of Exec. Board 1960
Mr. Tibor Horváth Commercial Director & Member of Exec. Board 1974
Mr. Istvan Hamecz Member of Exec. Board & Director NA
Ms. Katalin Erdei Member of Exec. Board NA
Attila Szenasi Member of the Exec. Board NA
Mr. Tamas Szolyak Member of Exec. Board NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions